CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer

Xiurong Li, John Kenneth Cowell, Khalid Sossey-Alaoui

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumor-igenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.

Original languageEnglish (US)
Pages (from-to)1474-1480
Number of pages7
JournalOncogene
Volume23
Issue number7
DOIs
StatePublished - Feb 19 2004

Fingerprint

Tumor Suppressor Genes
Breast Neoplasms
Tumor Cell Line
CpG Islands
Gene Silencing
Neoplasm Metastasis
Genes
Cell Line
Mutation
Chloride Channels
Genetic Promoter Regions
Epigenomics
Methylation
Neoplasms

Keywords

  • 1p31
  • Breast cancer
  • CLCA2
  • Epigenetics
  • Tumour suppressor gene

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. / Li, Xiurong; Cowell, John Kenneth; Sossey-Alaoui, Khalid.

In: Oncogene, Vol. 23, No. 7, 19.02.2004, p. 1474-1480.

Research output: Contribution to journalArticle

Li, Xiurong ; Cowell, John Kenneth ; Sossey-Alaoui, Khalid. / CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. In: Oncogene. 2004 ; Vol. 23, No. 7. pp. 1474-1480.
@article{e501540897234c6f9aaf5c480438627b,
title = "CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer",
abstract = "The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumor-igenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.",
keywords = "1p31, Breast cancer, CLCA2, Epigenetics, Tumour suppressor gene",
author = "Xiurong Li and Cowell, {John Kenneth} and Khalid Sossey-Alaoui",
year = "2004",
month = "2",
day = "19",
doi = "10.1038/sj.onc.1207249",
language = "English (US)",
volume = "23",
pages = "1474--1480",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer

AU - Li, Xiurong

AU - Cowell, John Kenneth

AU - Sossey-Alaoui, Khalid

PY - 2004/2/19

Y1 - 2004/2/19

N2 - The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumor-igenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.

AB - The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumor-igenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.

KW - 1p31

KW - Breast cancer

KW - CLCA2

KW - Epigenetics

KW - Tumour suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=1442308340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442308340&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207249

DO - 10.1038/sj.onc.1207249

M3 - Article

VL - 23

SP - 1474

EP - 1480

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -